This study aimed to assess the secondary benefits and adverse effects of botulinum toxin A injections into the parotid and submandibular glands in children with developmental disability and to determine whether these effects are related to reduction in drooling. Twenty-six children were injected (14 boys and 12 girls; mean age, 11 years 3 months). The Drooling Impact Scale and a secondary effects questionnaire covering aspects of eating, speech, saliva management, and sleep, were administered to the main carer at specific times before and after injection. Group mean preinjection and postinjection item and domain scores were compared using paired t tests. Change scores were calculated; individually categorized as improvement, no change, or deterioration; and related to change in drooling scores using linear regression analysis. Over 4 weeks, evidence of improvement was seen for the entire group with respect to drooling (P < 0.001), eating (P = 0.05), speech (P = 0.04), and sleep (P = 0.01), but not saliva management. Conversely, a minority of families reported worsening of eating skills after the injections that was directly related to lack of improvement in drooling. Because a minority of children unpredictably experience temporary adverse effects after botulinum toxin A injections into the salivary glands, swallowing function and nutritional status should be taken into account before proceeding with treatment.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1097/SCS.0b013e31827102a0 | DOI Listing |
Pain Pract
February 2025
Department of Anesthesiology and Pain Management, Leiden University Medical Center, Leiden, The Netherlands.
Introduction: Pain from the cervical facet joints, either due to degenerative conditions or due to whiplash-related trauma, is very common in the general population. Here, we provide an overview of the literature on the diagnosis and treatment of cervical facet-related pain with special emphasis on interventional treatment techniques.
Methods: A literature search on the diagnosis and treatment of cervical facet joint pain and whiplash-associated disorders (WAD) was performed using PubMed, Cochrane, and Embase databases.
Dermatol Surg
January 2025
Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan Province, P.R. China.
Background: Androgenetic alopecia (AGA) is a prevalent condition that significantly affects the psychosocial well-being of many individuals, and its treatment remains a clinical challenge. Botulinum toxin (BTX) injections have been reported to have a therapeutic effect on AGA. Although several studies have explored the efficacy and safety of this novel treatment, most are clinical studies with small sample sizes.
View Article and Find Full Text PDFCNS Neurol Disord Drug Targets
January 2025
The Movement Disorders Unit, Shaare Zedek Medical Center, Jerusalem.
Background: Botulinum Toxin type A (BonTA) is the preferred treatment for Cervical Dystonia (CD). However, the success rate is often suboptimal. One of the reasons for treatment failure is the in accuracy of injections.
View Article and Find Full Text PDFJ Cosmet Dermatol
January 2025
Division in Anatomy and Developmental Biology, Department of Oral Biology, Human Identification Research Institute, BK21 FOUR Project, Yonsei University College of Dentistry, Seoul, South Korea.
Objective: Ultrasonographic examination is easy, fast, safe, and used in various fields; however, its application to the facial area has been limited. Complex anatomical structures are mixed within thin, soft tissues in the facial region; therefore, understanding their structural characteristics is crucial. This study aimed to use ultrasonography to obtain information on the layered structure and soft tissue thickness of the eye area around the orbicularis oculi muscle and provide guidance for clinical practice.
View Article and Find Full Text PDFFront Neurol
January 2025
Department of Neurology, Ibn Sina Hospital, Safat, Kuwait.
Background: OnabotulinumtoxinA (BoNT-A) is approved as a prophylactic treatment of chronic migraine (CM) only. We aimed to assess the efficacy and safety of BoNT-A in the treatment of episodic migraine (EM).
Methods: This is a prospective study included migraine patients, aged 18-65 years, and completed 1 year treatment with BoNT-A.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!